JP3334725B2 - Accelerator for reducing alcohol in the body, its metabolites and oral freshener - Google Patents
Accelerator for reducing alcohol in the body, its metabolites and oral freshenerInfo
- Publication number
- JP3334725B2 JP3334725B2 JP07876693A JP7876693A JP3334725B2 JP 3334725 B2 JP3334725 B2 JP 3334725B2 JP 07876693 A JP07876693 A JP 07876693A JP 7876693 A JP7876693 A JP 7876693A JP 3334725 B2 JP3334725 B2 JP 3334725B2
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- alcohol
- tea
- ethanol
- tea extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、過剰飲酒による弊害で
ある吐き気その他の不快感、悪心、嘔吐、二日酔い、め
まい或いは口臭などの不快な症状を防止するのに優れた
効果を発揮し得る医薬品乃至医薬部外品等としての体内
アルコール及びアルコール代謝物の低下促進剤、また医
薬部外品としての口中清涼剤に関する。BACKGROUND OF THE INVENTION The present invention relates to a medicament which can exert an excellent effect in preventing unpleasant symptoms such as nausea and other discomforts, nausea, vomiting, hangover, dizziness and bad breath which are adverse effects of excessive drinking. or decrease promoter in the body alcohol and alcohol metabolites as quasi Hinto, also medical
It relates to a mouthwash as a quasi-drug .
【0002】[0002]
【従来の技術】このような過剰飲酒による弊害である吐
き気その他の不快感、悪心、嘔吐、二日酔い、めまい或
いは口臭などの不快な症状は、従来の研究により体内に
残留するエタノール等のアルコールやその代謝物である
アセトアルデヒド等の作用が関係していると考えられて
いる。BACKGROUND ART Unpleasant symptoms such as nausea and other discomforts, nausea, vomiting, hangovers, dizziness or bad breath, which are adverse effects of excessive drinking, are caused by alcohol or alcohol such as ethanol remaining in the body by conventional research. It is believed that the action of metabolites such as acetaldehyde is involved.
【0003】そこで、上記症状を予防乃至抑制するため
に、これらの体内濃度を低下させる医薬品やこれに準じ
た医薬品外等の研究が進められている。なかでも天然植
物から抽出する成分に関しては、その安全性等の面から
特に注目されるところである。[0003] Therefore, in order to prevent or suppress the above-mentioned symptoms, researches on pharmaceuticals for reducing their concentration in the body and non-pharmaceuticals according to them have been conducted. In particular, components extracted from natural plants are particularly attracting attention in terms of safety and the like.
【0004】一方、茶に関しては、その種子中に多く含
有されているサポニン成分にアルコールの吸収阻害作用
があることは開示されているものの(特開平4−145
028)、上記体内アルコール、その代謝物の濃度を低
下促進させる作用については全く開示されていない。[0004] On the other hand, as for tea, it is disclosed that the saponin component contained in a large amount in the seed has an effect of inhibiting absorption of alcohol (Japanese Patent Laid-Open No. 4-145).
028) There is no disclosure of the action of accelerating the concentration of the above-mentioned in-vivo alcohol or its metabolite.
【0005】[0005]
【発明が解決しようとする課題】また、特に過剰飲酒し
た場合の不快な症状においては、単に薬理効果や安全性
に優れているというばかりではなく、香りや口当たりが
良く摂取しやすいことが大切である。In the case of unpleasant symptoms, especially when drinking excessively, not only is the pharmacological effect and safety excellent, but also the scent and mouthfeel are increased.
Well easy to ingest it is important.
【0006】そこで本発明者は、天然物である茶の日常
的に飲用されていることから証明される安全性、その豊
かな香り、或いは口当たりの清涼感又はその入手のしや
すさに着目し、茶の抽出方法並びにその抽出物の薬理効
果について研究を行ったところ、その熱水または有機溶
媒抽出成分等に体内アルコール等に対する低下促進作用
があることを見出すことに成功し、大量かつ安価に生産
が可能であると共に、優れた薬理効果を発揮することが
でき、かつ人体に対する安全性も高く、それでいて摂取
しすい体内アルコール、その代謝物の低下促進剤及び口
中清涼剤を究明したものである。Accordingly, the present inventor has focused on the safety of tea, which is a natural product, which is proven to be consumed on a daily basis, the rich aroma thereof, the refreshing sensation of mouthfeel, or the availability thereof. After conducting research on the extraction method of tea and the pharmacological effects of the extract, we succeeded in finding that the hot water or organic solvent extractables have the effect of promoting the reduction of alcohol in the body, etc. In addition to being capable of being produced, it can exhibit excellent pharmacological effects and is highly safe for the human body, and yet has investigated alcohol that is ingested, an accelerator for lowering its metabolites, and an oral freshener. .
【0007】[0007]
【課題を解決するための手段】上記課題を解決するもの
として、本発明者は、茶を熱水、または有機溶媒若しく
は熱水と有機溶媒の混合液により抽出して得られる成分
(以下茶抽出成分とする)を有効成分とする体内エタノ
ール及びアセトアルデヒドの低下促進剤を得ることに成
功し本発明をなしたものであり、この体内エタノール及
びアセトアルデヒドの低下促進剤の有効性は動物実験に
より明らかにすることができた。Means for Solving the Problems To solve the above-mentioned problems, the present inventor has proposed a component obtained by extracting tea with hot water or an organic solvent or a mixture of hot water and an organic solvent (hereinafter referred to as tea extraction). The present invention has been achieved by successfully obtaining an in-vivo ethanol and acetaldehyde lowering accelerator containing the above-mentioned active ingredient as an active ingredient, and the effectiveness of the in-vivo ethanol and acetaldehyde lowering accelerator has been clarified by animal experiments. We were able to.
【0008】なお、本発明においては、茶は、一般に緑
茶、ウーロン茶、紅茶などの原料となる総称を示すもの
であり、茶葉、茶種子、樹皮などの各部位、或いは全体
(Camellia sinennsis)を示すものである。In the present invention, tea is a general term used as a raw material for green tea, oolong tea, black tea, etc., and refers to each part of tea leaves, tea seeds, bark, etc., or the whole (Camellia sinennsis). Things.
【0009】上記茶抽出成分は、カテキン類を主成分と
するものであり、その他に灰分、遊離アミノ酸、カフェ
イン、糖分、たんぱく質、脂質、ビタミンC、及びその
他の物質を含有しており、この組成からも人体に対する
安全性を確認できた。The above-mentioned tea extract is mainly composed of catechins, and further contains ash, free amino acids, caffeine, sugar, protein, lipid, vitamin C, and other substances. The safety for the human body was confirmed from the composition.
【0010】この茶抽出成分を得るには、例えば、茶葉
を定法に従って荒茶加工し、これを熱水、または、エタ
ノール等の有機溶媒若しくは熱水とこれらの有機溶媒の
混合液を抽出溶媒に用いて所定温度で所定時間抽出を行
った後、この抽出液を濾過乃至遠心分離し、得られた濾
液乃至抽出液を濃縮し乾燥すればよい。[0010] In order to obtain this tea extract component, for example, tea leaves are processed into crude tea according to a standard method, and this is treated with hot water or an organic solvent such as ethanol or a mixture of hot water and these organic solvents as an extraction solvent. After performing extraction at a predetermined temperature for a predetermined time, the extract may be filtered or centrifuged, and the obtained filtrate or extract may be concentrated and dried.
【0011】こうして得られた茶抽出成分は、そのまま
本発明の有効成分として利用することができ、これを有
効成分として透析、除菌濾過、加熱処理、凍結乾燥等の
処理を施すことにより医薬品乃至医薬部外品等として提
供することができる。The thus-obtained tea extract can be used as an active ingredient of the present invention as it is, and it can be used as a medicinal product by subjecting it to dialysis, sterilization filtration, heat treatment, freeze-drying and the like. It can be provided as a quasi-drug or the like.
【0012】さらに、茶抽出成分を所定の濃度、好まし
くは0.1乃至5%前後に調整して丸状、環円状、若し
くは板状等の錠剤若しくはカプセル状等に成形するか、
或いは粉末状若しくは液状にして褐色瓶容器等に詰め、
医薬部外品としての口中清涼剤として提供することもで
きる。Further, the tea extract component is adjusted to a predetermined concentration, preferably about 0.1 to 5%, and formed into tablets, capsules, or the like having a round shape, a ring shape, a plate shape, or the like.
Alternatively, make it into a powder or liquid and pack it in a brown bottle container,
It can also be provided as a mouthwash as a quasi-drug .
【0013】尚、上記茶抽出成分に甘味剤、香味剤、保
存料を加えて提供すれば、より摂取しやすくなり、好ま
しい。[0013] It is preferable to provide a sweetener, a flavoring agent, and a preservative in addition to the above-mentioned tea-extracting component, because it becomes easier to ingest.
【0014】[0014]
【発明の効果】飲酒前、過剰飲酒した際、或いは過剰飲
酒して不快な症状を感じた際などに本発明に係わる体内
エタノール及びアセトアルデビトの低下促進剤或いは口
中清涼剤を摂取することにより、主成分であるカテキン
類等の作用により血液中及び肝臓中のエタノール及びア
セトアルデヒドの濃度は低下が促進され、過剰飲酒によ
る様々な不快な症状を予防或いは抑制することができ
る。また、組成成分から安全性が確かめられているの
で、安心して摂取することができる。EFFECT OF THE INVENTION Before drinking, when drinking excessively, or when feeling unpleasant due to excessive drinking, etc., the ingestion of the ethanol or acetoaldevit lowering accelerator or the oral freshener in the body according to the present invention is mainly used. By the action of catechins and the like as components, the concentration of ethanol and acetaldehyde in blood and liver is promoted to decrease, and various unpleasant symptoms due to excessive drinking can be prevented or suppressed. In addition, since the safety has been confirmed from the components, it can be taken with confidence.
【0015】[0015]
(茶抽出成分の製造方法とその組成分析)新鮮葉(Thea
sinensis L.)を定法に従って荒茶加工し、この乾燥葉
10kgに対して90°Cの精製水を100l加え、9
0°Cで10分間抽出した後、抽出液の濾過乃至遠心分
離を行い、さらにこれを濃縮し、乾燥させて2.5kg
の乾燥粉末状の茶抽出成分を得た。(Method of producing tea extract and analysis of its composition) Fresh leaves (Thea
sinensis L.) according to a standard method, and 100 kg of 90 ° C. purified water is added to 10 kg of the dried leaves.
After extraction at 0 ° C. for 10 minutes, the extract is filtered or centrifuged, and further concentrated and dried to 2.5 kg.
A dry powdered tea extract was obtained.
【0016】そして、この茶抽出成分の組成分析を行っ
たところ、水分3.7%、灰分8.0%、遊離アミノ酸
3.9%、カテキン類30.0%(EGC10.0%、
EGCg14.3%、EC1.8%、ECG3.4%、
その他0.5%)、カフェイン5.2%、糖分8.3
%、タンパク質8.9%、脂質0.2%、ビタミンC
1.0%、その他(粗繊維、有機酸、色素、フラボノイ
ド、揮発性香気成分)30.8%を含有する組成である
ことが分かった。When the composition of the tea extract was analyzed, the water content was 3.7%, the ash content was 8.0%, the free amino acids were 3.9%, and the catechins were 30.0% (EGC 10.0%,
EGCg 14.3%, EC 1.8%, ECG 3.4%,
Others 0.5%), caffeine 5.2%, sugar content 8.3
%, Protein 8.9%, fat 0.2%, vitamin C
It was found that the composition contained 1.0% and 30.8% of other components (crude fiber, organic acid, pigment, flavonoid, volatile odor component).
【0017】(マウスによる投与試験)そこで、粗カテ
キンを蒸留水に溶かし、これをICR系雄マウス(n=3×
2 ×3)に対して体重1kg当たり500mgだけ経口投
与し、その後1時間経過後にエタノールを体重1kg当
たり2g(20%W/V)だけカテーテルを用いて経口投与し
た。また、コントロールとして蒸留水を同様に経口投与
した。そして、エタノール投与前、エタノール投与後1
時間後、3時間後に血液及び肝臓の採取を行い、血液中
及び肝臓中のエタノール、アセトアルデヒド、アセテー
ト及びアセトンの濃度をそれぞれ測定した。(Administration test using mice) Then, the crude catechin was dissolved in distilled water, and this was dissolved in an ICR male mouse (n = 3 ×
2 × 3) was orally administered at a dose of 500 mg / kg body weight, and after 1 hour, ethanol was orally administered at a dose of 2 g / kg body weight (20% W / V) using a catheter. As a control, distilled water was orally administered in the same manner. And before ethanol administration and 1 after ethanol administration
After 3 hours, blood and liver were collected, and the concentrations of ethanol, acetaldehyde, acetate and acetone in the blood and liver were measured, respectively.
【0018】この時の測定方法は以下の通りである。先
ず、血液0.5ml、及び肝臓0.5gでは液体窒素を
用い粉末状にして、直ちに冷却したPCA試薬(0.6N p
erchloric acid, 30mM thiourea, 0.1mM EDTA in salin
e )2.5mlを混合し、4°C、3000rpmで1
0分間遠心分離する。The measuring method at this time is as follows. First, 0.5 ml of blood and 0.5 g of liver were powdered using liquid nitrogen, and immediately cooled PCA reagent (0.6 N p
erchloric acid, 30mM thiourea, 0.1mM EDTA in salin
e) Mix 2.5 ml and add 1 at 3000 rpm at 4 ° C.
Centrifuge for 0 minutes.
【0019】次に、得られた上清試料を二分し、一方
(A)をエタノール、アセトアルデヒドおよびアセトン
測定用のバイアル瓶に1mlを入れ、他方(B)をアセ
テートの測定用のバイアル瓶に入れ、メタノール100
μlと硫酸50μlを加えメチル化した。さらに、内部
標準物質としてAのバイアル瓶には0.0003%t−
ブタノール0.1mlを入れ、Bのバイアル瓶には0.
02%n−ブタノール0.1mlを入れる。そして、A
のバイアル瓶を65°Cで15分間、Bのバイアル瓶を
55°Cで30分間加熱した後、GCで定量分析を行っ
た。Next, the obtained supernatant sample was bisected, and one (A) was placed in a vial for measuring ethanol, acetaldehyde and acetone, and the other (B) was placed in a vial for measuring acetate. , Methanol 100
μl and 50 μl of sulfuric acid were added for methylation. In addition, 0.0003% t-
0.1 ml of butanol was added, and 0.1 ml was added to the B vial.
Add 0.1 ml of 02% n-butanol. And A
The vial was heated at 65 ° C. for 15 minutes, and the vial of B was heated at 55 ° C. for 30 minutes, and then quantitatively analyzed by GC.
【0020】図1乃至図8は、この結果をそれぞれ示し
たものであり、図1は粗カテキン投与した場合とコント
ロールの場合の血中のエタノール濃度の変化を、図2は
同じく血中のアセトアルデヒド濃度の変化を、図3は同
じく血中のアセテート濃度の変化を、図4は同じく血中
のアセトン濃度の変化を、図5は同じく肝臓内のエタノ
ール濃度の変化を、図6は同じく肝臓内のアセトアルデ
ヒド濃度の変化を、図7は同じく肝臓内のアセテート濃
度の変化を、そして図8は同じく肝臓内のアセトン濃度
の変化を、それぞれ経時的に示している。FIGS. 1 to 8 show the results, respectively. FIG. 1 shows the change in the ethanol concentration in the blood when the crude catechin was administered and the control, and FIG. 2 shows the acetaldehyde in the blood. 3 shows the change in the acetate concentration in the blood, FIG. 4 shows the change in the acetone concentration in the blood, FIG. 5 shows the change in the ethanol concentration in the liver, and FIG. 7 shows the change in the acetaldehyde concentration in the liver, FIG. 7 shows the change in the acetate concentration in the liver, and FIG. 8 also shows the change in the acetone concentration in the liver over time.
【0021】この結果からコントロールに比較して粗カ
テキンを投与した場合、血液中及び肝臓中のエタノール
及びアセトアルデヒドの濃度の消失が早いことが判明し
た。一方、血液中及び肝中のアセテートの濃度及びアセ
トンの濃度は、逆にコントロールに比較して高くなって
いる。これより、粗カテキン投与によってアルコールの
代謝が促進されたことも判明した。From these results, it was found that when crude catechin was administered as compared with the control, the concentration of ethanol and acetaldehyde in blood and liver disappeared earlier. On the other hand, the concentrations of acetate and acetone in the blood and liver are higher than those of the control. This also revealed that the administration of crude catechin promoted alcohol metabolism.
【0022】従って、カテキン類を主成分とする上記茶
抽出成分も同様に作用すると考えることができ、本発明
に係わる体内エタノール及びアセトアルデヒドの低下促
進剤、及び口中清涼剤に、体内エタノール及びアセトア
ルデヒドの濃度を低下させる作用があることを確認で
き、また同時に、体内中のアルコール及びアセトアルデ
ヒドの代謝を促進する作用のあることも判明した。Therefore, it can be considered that the above-mentioned tea extract component containing catechins as a main component also acts in the same manner, and the ethanol and acetaldehyde lowering promoters in the body and the mouth freshener according to the present invention include ethanol and acetaldehyde in the body. It was confirmed that it had an effect of lowering the concentration, and at the same time, it was found that it had an effect of promoting the metabolism of alcohol and acetaldehyde in the body.
【0023】(製造例)上記方法にて得られた茶抽出物
を飲用濃度として好ましいように、抽出物を乾燥粉末に
換算して重量%濃度で、0.1〜5%前後の濃度に調整
して、これに香味剤、甘味剤、及び保存料等を加え、1
00 mlの褐色瓶容器に詰、或いは、カプセル若しく
は錠剤等にして、製品化することができる。(Production Example) The tea extract obtained by the above method is adjusted to a concentration of about 0.1 to 5% by weight in terms of dry powder so that the extract is converted into a dry powder so as to be preferable as a drinking concentration. And add flavoring agents, sweetening agents, preservatives, etc.
It can be put into a 00 ml amber bottle container, or made into a capsule or a tablet and commercialized.
【図1】血中のエタノール濃度を経時的に示したグラフ
である。FIG. 1 is a graph showing the concentration of ethanol in blood over time.
【図2】血中のアセトアルデヒド濃度を経時的に示した
グラフである。FIG. 2 is a graph showing acetaldehyde concentration in blood over time.
【図3】血中のアセテート濃度を経時的に示したグラフ
である。FIG. 3 is a graph showing the acetate concentration in blood over time.
【図4】血中のアセトン濃度を経時的示したグラフであ
る。FIG. 4 is a graph showing the concentration of acetone in blood over time.
【図5】肝臓内のエタノール濃度を経時的に示したグラ
フである。FIG. 5 is a graph showing the concentration of ethanol in the liver over time.
【図6】肝臓内のアセトアルデヒド濃度を経時的に示し
たグラフである。FIG. 6 is a graph showing the concentration of acetaldehyde in the liver over time.
【図7】肝臓内のアセテート濃度を経時的に示したグラ
フである。FIG. 7 is a graph showing the acetate concentration in the liver over time.
【図8】肝臓内のアセトン濃度を経時的に示したグラフ
である。FIG. 8 is a graph showing the acetone concentration in the liver over time.
───────────────────────────────────────────────────── フロントページの続き 審査官 鶴見 秀紀 (56)参考文献 CHEMICAL ABSTRACT S,1969,Vol.70,No.7,pp 158,70:27240 (58)調査した分野(Int.Cl.7,DB名) A61K 35/78 A61K 7/26 A61K 31/35 BIOSIS(DIALOG) CA(STN) MEDLINE(STN)──────────────────────────────────────────────────続 き Continuing from the front page Examiner Hideki Tsurumi (56) References CHEMICAL ABSTRACT S, 1969, Vol. 70, No. 7, pp 158, 70: 27240 (58) Fields investigated (Int. Cl. 7 , DB name) A61K 35/78 A61K 7/26 A61K 31/35 BIOSIS (DIALOG) CA (STN) MEDLINE (STN)
Claims (3)
と有機溶媒との混合液によって抽出して得られるカテキ
ン類を主成分とする茶抽出成分を有効成分とする体内ア
ルコール、アルコール代謝物の低下促進剤。The method according to claim 1] Brown, obtained by extracting with hot water or an organic solvent, or a mixed solution of hot water and an organic solvent Kateki
A promoter for lowering alcohol in the body and metabolites of alcohol, which contains as an active ingredient a tea extract component mainly containing carbohydrates.
に調整し、錠剤若しくはカプセル状に成形するか、或い
は粉状若しくは液状として得られる過剰飲酒による不快
な症状の予防用或いは抑制用口中清涼剤。2. The unpleasantness due to excessive drinking obtained by adjusting the tea extract component according to claim 1 to an appropriate concentration and molding it into tablets or capsules, or obtained as a powder or liquid.
Oral freshener for preventing or suppressing various symptoms .
前後にすることを特徴とする請求項2に記載の口中清涼
剤。3. The content of the tea extract component is 0.1 to 5 % by weight.
3. The mouth freshener according to claim 2 , wherein the mouth freshener is used.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP07876693A JP3334725B2 (en) | 1993-03-12 | 1993-03-12 | Accelerator for reducing alcohol in the body, its metabolites and oral freshener |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP07876693A JP3334725B2 (en) | 1993-03-12 | 1993-03-12 | Accelerator for reducing alcohol in the body, its metabolites and oral freshener |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06263648A JPH06263648A (en) | 1994-09-20 |
JP3334725B2 true JP3334725B2 (en) | 2002-10-15 |
Family
ID=13671031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP07876693A Expired - Lifetime JP3334725B2 (en) | 1993-03-12 | 1993-03-12 | Accelerator for reducing alcohol in the body, its metabolites and oral freshener |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3334725B2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571441A (en) * | 1994-11-01 | 1996-11-05 | The Procter & Gamble Company | Nutrient supplement compositions providing physiologic feedback |
KR0181168B1 (en) * | 1996-11-07 | 1999-02-01 | 남종현 | Hangover natural tea and its manufacturing method |
JP4777495B2 (en) * | 1999-04-01 | 2011-09-21 | 森下仁丹株式会社 | Alcohol disorder preventive agent and food containing the same |
JP4754190B2 (en) * | 2003-06-30 | 2011-08-24 | 株式会社東洋新薬 | Alcohol metabolism improver |
EP1684737A4 (en) * | 2003-11-07 | 2009-11-11 | Oaky Natural Co Ltd | Pharmaceutical composition containing guaiacol derivatives and syringol derivatives extracted from natural plant vinegar |
JP5357374B2 (en) * | 2004-04-19 | 2013-12-04 | 丸善製薬株式会社 | Alcohol concentration reducing agent for exhaled breath and food and drink, and method for reducing alcohol concentration in exhaled breath after drinking |
JP5284104B2 (en) * | 2006-11-30 | 2013-09-11 | サッポロビール株式会社 | Mouth freshener |
JP5700956B2 (en) * | 2010-05-31 | 2015-04-15 | ハウス食品グループ本社株式会社 | Container turmeric beverage |
JP2016030723A (en) * | 2014-07-25 | 2016-03-07 | 株式会社ロッテ | Composition for aldehyde reduction |
WO2018012197A1 (en) * | 2016-07-15 | 2018-01-18 | 花王株式会社 | Instant powdered tea |
CN109475142A (en) * | 2016-07-15 | 2019-03-15 | 花王株式会社 | instant powder tea |
-
1993
- 1993-03-12 JP JP07876693A patent/JP3334725B2/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS,1969,Vol.70,No.7,pp158,70:27240 |
Also Published As
Publication number | Publication date |
---|---|
JPH06263648A (en) | 1994-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2245812T3 (en) | COMPOSITION TO INHIBIT AN INCREASE IN THE BLOOD SUGAR LEVEL OR DECREASE THE BLOOD SUGAR LEVEL. | |
CN108434231B (en) | Medicinal and edible Chinese medicinal composition for resisting drunkenness and dispelling effects of alcohol and preparation method thereof | |
JP3875733B2 (en) | Body acetaldehyde metabolism promoter and method for producing the same | |
JP3334725B2 (en) | Accelerator for reducing alcohol in the body, its metabolites and oral freshener | |
JP6211500B2 (en) | Brown adipocyte activator | |
WO2006056129A1 (en) | Compositions of huperzia serrata alkaloids comprising huperzine a and huperzine b and preparation thereof | |
KR20010049156A (en) | The extract of pine needle and the use thereof | |
US11596664B2 (en) | Plant extracts made of Sideritis and use thereof to boost cognitive performance | |
JPH10508880A (en) | Pharmaceutical composition for diabetes | |
KR20020092082A (en) | Tonic composition | |
JP2002524419A (en) | Compositions for improving mental performance in mammals | |
JP3130327B2 (en) | Liver dysfunction preventive agent and functional food having hepatic dysfunction preventive action | |
KR100512912B1 (en) | Alcohol metabolism herbal medicine accelerator | |
KR20180019845A (en) | Composition for Treating Hangover Comprising Extract of Protaetia Orientalis Larva and Hovenia Dulcis Fruit | |
JPH0959154A (en) | Antidote | |
CN108714164A (en) | The purposes of Folium Forsythia black tea extract | |
CN100569234C (en) | Composition of total ginkgolides with neuroprotective effect | |
JPH08277221A (en) | Suppressant for alcohol absorption | |
JP5546833B2 (en) | Acetaldehyde / ethanol reducing agent | |
CN112007092A (en) | Anti-alcohol composition and preparation method thereof | |
JPH06340542A (en) | Bone disease-preventing and treating agent originated from medicinal plant | |
KR20010009653A (en) | Composition for treating sexual dysfunction | |
JP2955679B2 (en) | Ethanol metabolism promoter | |
US20040146468A1 (en) | Oral compositon comprising an extract from the bark of albizzia myrioplylla | |
JP3167776B2 (en) | Anticancer / anticancer agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080802 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110802 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130802 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term |